EXUMA Biotech
Dr. Gregory Wade has served as EXUMA Biotech’s Chief Business Officer since January 2022. Dr. Wade has over 20 years-experience in the biotechnology industry. Most recently, he held the position Managing Director, Capital Markets Advisory, and Co-Lead of the West Coast Region for Danforth Advisors. From 2015-2021, Dr. Wade was a Managing Director in BTIG’s Healthcare Investment Banking Group. Prior to his role with BTIG, Dr. Wade served as Head of Business Development at Pharmacyclics, a role he held following 16 years of work in healthcare equity research at Pacific Growth Equities and its successor, Wedbush PacGrow. Dr. Wade earned his undergraduate degree in biophysics, and his Ph.D. in physiology, from Western University in London, Canada.
EXUMA Biotech
EXUMA Biotech is a clinical-stage biotechnology company committed to bringing to market CAR-T therapies for the treatment of cancer. Founded in 2015, the company has rapidly built its core technologies and a growing global presence with operations in China (Shanghai and Shenzhen), Grand Cayman, and across the US with sites in West Palm Beach and San Diego.